Medtechy

TransEnterix Provides Senhance Sales Update

Posted on January 07, 2019


As TransEnterix CEO, Todd Pope, gets ready to present at the J.P. Morgan Healthcare Conference later this afternoon, the company provided a corporate update highlighting their capital sales and revenue for the fourth quarter.

In late December, we wrote that fourth quarter capital sales, specifically within the U.S. were important as investors and analysts use that data to measure traction of the Senhance system.

During the quarter, TransEnterix sold five Senhance Systems, with one sold in the U.S, three sold in the EMEA (Europe, Middle East, and Africa) region and one in Asia.

It will be important to hear what Todd Pope has to say about their capital sales traction during his presentation this afternoon at the J.P. Morgan Healthcare Conference.

What else to know:

  • Total 2018 revenue is expected to be approximately $24.0 million, an increase of 238% over the prior year. In 2018, the Company sold 15 Senhance Systems.
  • Achieved preliminary unaudited revenue of approximately $7.4 million for the fourth quarter of 2018
  • Received Taiwanese FDA approval for the Senhance System instruments in fourth quarter of 2018
  • Launched Ultrasonic Instrument System in CE Mark countries in fourth quarter of 2018 Preliminary unaudited cash and cash equivalents of approximately $73 million as of December 31, 2018

“2018 was a significant year for TransEnterix as we continued to drive the global commercial adoption of the Senhance System and made great strides towards expanding the applicability of the system to a greater number of surgeons and hospitals across the globe," said Todd M. Pope, president and CEO at TransEnterix. “We view 2019 as an opportunity to leverage the tremendous progress we made in 2018 and bring the benefits of Senhance Surgery to more patients, surgeons and hospitals both in the U.S and internationally.”

Check back for our thoughts on Todd Pope's presentation this afternoon at the J.P. Morgan Healthcare Conference.